vs
Side-by-side financial comparison of Eightco Holdings Inc. (ORBS) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Eightco Holdings Inc. is the larger business by last-quarter revenue ($10.2M vs $5.5M, roughly 1.9× Taysha Gene Therapies, Inc.). Taysha Gene Therapies, Inc. runs the higher net margin — -507.8% vs -2281.6%, a 1773.9% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs -49.9%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs 13.1%).
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
ORBS vs TSHA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.2M | $5.5M |
| Net Profit | $-232.5M | $-27.9M |
| Gross Margin | -13.0% | — |
| Operating Margin | -475.0% | -516.0% |
| Net Margin | -2281.6% | -507.8% |
| Revenue YoY | -49.9% | 171.3% |
| Net Profit YoY | -9183.3% | -48.3% |
| EPS (diluted) | $-2.34 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $10.2M | $5.5M | ||
| Q3 25 | $5.3M | $0 | ||
| Q2 25 | $7.6M | $2.0M | ||
| Q1 25 | $9.9M | $2.3M | ||
| Q4 24 | $20.3M | $2.0M | ||
| Q3 24 | $6.1M | $1.8M | ||
| Q2 24 | $5.3M | $1.1M | ||
| Q1 24 | $8.0M | $3.4M |
| Q4 25 | $-232.5M | $-27.9M | ||
| Q3 25 | $-25.8M | $-32.7M | ||
| Q2 25 | $-1.2M | $-26.9M | ||
| Q1 25 | $-2.5M | $-21.5M | ||
| Q4 24 | $-2.5M | $-18.8M | ||
| Q3 24 | $-3.2M | $-25.5M | ||
| Q2 24 | $4.4M | $-20.9M | ||
| Q1 24 | $1.9M | $-24.1M |
| Q4 25 | -13.0% | — | ||
| Q3 25 | -3.7% | — | ||
| Q2 25 | 16.4% | — | ||
| Q1 25 | 8.2% | — | ||
| Q4 24 | 8.2% | — | ||
| Q3 24 | 26.5% | — | ||
| Q2 24 | 25.1% | — | ||
| Q1 24 | 17.5% | — |
| Q4 25 | -475.0% | -516.0% | ||
| Q3 25 | -116.9% | — | ||
| Q2 25 | -15.9% | -1347.1% | ||
| Q1 25 | -14.3% | -930.5% | ||
| Q4 24 | -11.9% | -985.8% | ||
| Q3 24 | -29.1% | -1448.4% | ||
| Q2 24 | -16.4% | -1915.4% | ||
| Q1 24 | -39.6% | -713.3% |
| Q4 25 | -2281.6% | -507.8% | ||
| Q3 25 | -487.6% | — | ||
| Q2 25 | -15.4% | -1353.6% | ||
| Q1 25 | -25.7% | -935.2% | ||
| Q4 24 | -12.3% | -929.0% | ||
| Q3 24 | -52.5% | -1427.5% | ||
| Q2 24 | 84.2% | -1882.0% | ||
| Q1 24 | 24.4% | -705.4% |
| Q4 25 | $-2.34 | $-0.08 | ||
| Q3 25 | $-0.58 | $-0.09 | ||
| Q2 25 | $-0.38 | $-0.09 | ||
| Q1 25 | $-0.84 | $-0.08 | ||
| Q4 24 | $-1.44 | $-0.07 | ||
| Q3 24 | $-1.77 | $-0.10 | ||
| Q2 24 | $2.15 | $-0.09 | ||
| Q1 24 | $1.42 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $58.5M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $232.6M | $246.9M |
| Total Assets | $250.2M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $58.5M | $319.8M | ||
| Q3 25 | $23.7M | $297.3M | ||
| Q2 25 | $696.3K | $312.8M | ||
| Q1 25 | $434.4K | $116.6M | ||
| Q4 24 | $239.2K | $139.0M | ||
| Q3 24 | $2.4M | $157.7M | ||
| Q2 24 | $363.1K | $172.7M | ||
| Q1 24 | $808.8K | $124.0M |
| Q4 25 | $232.6M | $246.9M | ||
| Q3 25 | $339.2M | $219.0M | ||
| Q2 25 | $8.9M | $248.7M | ||
| Q1 25 | $9.7M | $55.1M | ||
| Q4 24 | $11.9M | $71.5M | ||
| Q3 24 | $13.0M | $88.8M | ||
| Q2 24 | $13.8M | $108.9M | ||
| Q1 24 | $3.9M | $53.8M |
| Q4 25 | $250.2M | $343.3M | ||
| Q3 25 | $355.5M | $316.6M | ||
| Q2 25 | $48.7M | $333.3M | ||
| Q1 25 | $47.6M | $138.4M | ||
| Q4 24 | $50.8M | $160.4M | ||
| Q3 24 | $49.2M | $180.2M | ||
| Q2 24 | $48.4M | $200.4M | ||
| Q1 24 | $50.2M | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.0M | $-26.7M |
| Free Cash FlowOCF − Capex | $-11.0M | — |
| FCF MarginFCF / Revenue | -107.7% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.0M | $-26.7M | ||
| Q3 25 | $-1.6M | $-24.2M | ||
| Q2 25 | $-659.2K | $-20.2M | ||
| Q1 25 | $999.8K | $-22.0M | ||
| Q4 24 | $-6.6M | $-18.3M | ||
| Q3 24 | $77.7K | $-21.6M | ||
| Q2 24 | $-440.3K | $-21.5M | ||
| Q1 24 | $-723.3K | $-19.8M |
| Q4 25 | $-11.0M | — | ||
| Q3 25 | — | $-24.3M | ||
| Q2 25 | $-661.3K | — | ||
| Q1 25 | $999.7K | — | ||
| Q4 24 | $-6.6M | $-18.3M | ||
| Q3 24 | $73.0K | $-21.6M | ||
| Q2 24 | — | $-21.7M | ||
| Q1 24 | — | $-19.9M |
| Q4 25 | -107.7% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -8.7% | — | ||
| Q1 25 | 10.1% | — | ||
| Q4 24 | -32.7% | -905.5% | ||
| Q3 24 | 1.2% | -1210.9% | ||
| Q2 24 | — | -1951.9% | ||
| Q1 24 | — | -584.5% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | 0.1% | ||
| Q3 24 | 0.1% | 2.0% | ||
| Q2 24 | — | 18.1% | ||
| Q1 24 | — | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -0.10× | — | ||
| Q1 24 | -0.37× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
